Alzinova announces a delay in the supply of material for the clinical trial due to additional analytical work
Alzinova AB announces today that the manufacture of the drug substance for the Phase 1b clinical trial in Alzheimer's disease patients with the ALZ-101 vaccine has been delayed, as additional analytical work must be performed.As previously disclosed, Alzinova has switched to a new supplier of the drug substance used for the ALZ-101 vaccine. According to plan, a technical batch of non-GMP (Good Manufacturing Practice) drug product was delivered on schedule during the second quarter. The purity of this batch was found to be higher than that of the drug substance produced by the previous